Radiation plus two immunotherapy drugs shows promise in advanced cancers
NCT ID NCT02639026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanoma, lung, breast, or pancreatic cancer who had not responded to standard treatments. The main goal was to find the best dose and schedule while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States